Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment
Open Access
- 9 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Molecular Medicine
- Vol. 91 (7), 883-899
- https://doi.org/10.1007/s00109-013-0992-6
Abstract
Tumor hypoxia is a characteristic of cancer cell growth and invasion, promoting angiogenesis, which facilitates metastasis. Oxygen delivery remains impaired because tumor vessels are anarchic and leaky, contributing to tumor cell dissemination. Counteracting hypoxia by normalizing tumor vessels in order to improve drug and radio therapy efficacy and avoid cancer stem-like cell selection is a highly challenging issue. We show here that inositol trispyrophosphate (ITPP) treatment stably increases oxygen tension and blood flow in melanoma and breast cancer syngeneic models. It suppresses hypoxia-inducible factors (HIFs) and proangiogenic/glycolysis genes and proteins cascade. It selectively activates the tumor suppressor phosphatase and tensin homolog (PTEN) in vitro and in vivo at the endothelial cell (EC) level thus inhibiting PI3K and reducing tumor AKT phosphorylation. These mechanisms normalize tumor vessels by EC reorganization, maturation, pericytes attraction, and lowering progenitor cells recruitment in the tumor. It strongly reduces vascular leakage, tumor growth, drug resistance, and metastasis. ITPP treatment avoids cancer stem-like cell selection, multidrug resistance (MDR) activation and efficiently enhances chemotherapeutic drugs activity. These data show that counteracting tumor hypoxia by stably restoring healthy vasculature is achieved by ITPP treatment, which opens new therapeutic options overcoming hypoxia-related limitations of antiangiogenesis-restricted therapies. By achieving long-term vessels normalization, ITPP should provide the adjuvant treatment required in order to overcome the subtle definition of therapeutic windows for in vivo treatments aimed by the current strategies against angiogenesis-dependent tumors.Keywords
This publication has 48 references indexed in Scilit:
- Nitric oxide modulates the expression of endothelial cell adhesion molecules involved in angiogenesis and leukocyte recruitmentExperimental Cell Research, 2011
- Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular LeakageCancer Cell, 2010
- Soluble forms of VEGF receptor‐1 and ‐2 promote vascular maturationviamural cell recruitmentThe FASEB Journal, 2010
- Osteopontin: An Effector and an Effect of Tumor MetastasisCurrent Molecular Medicine, 2010
- Prolyl Hydroxylases 2 and 3 Act in Gliomas as Protective Negative Feedback Regulators of Hypoxia-Inducible FactorsCancer Research, 2010
- Factors Interacting with HIF-1α mRNA: Novel Therapeutic TargetsCurrent Pharmaceutical Design, 2009
- Tumor Vascular Changes Mediated by Inhibition of Oncogenic SignalingCancer Research, 2009
- Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cellsBlood, 2009
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- A SV‐40 immortalized murine endothelial cell line from peripheral lymph node high endothelium expresses a new α‐L‐fucose binding proteinBiology of the Cell, 1993